242 related articles for article (PubMed ID: 7988266)
1. Impact of neuroendocrine differentiation in non-small cell lung cancer. The LCSG experience.
Linnoila RI; Piantadosi S; Ruckdeschel JC
Chest; 1994 Dec; 106(6 Suppl):367S-371S. PubMed ID: 7988266
[TBL] [Abstract][Full Text] [Related]
2. The prognostic significance of neuroendocrine markers and carcinoembryonic antigen in patients with resected stage I and II non-small cell lung cancer.
Graziano SL; Tatum AH; Newman NB; Oler A; Kohman LJ; Veit LJ; Gamble GP; Coleman MJ; Barmada S; O'Lear S
Cancer Res; 1994 Jun; 54(11):2908-13. PubMed ID: 8187076
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine differentiation in endocrine and nonendocrine lung carcinomas.
Linnoila RI; Mulshine JL; Steinberg SM; Funa K; Matthews MJ; Cotelingam JD; Gazdar AF
Am J Clin Pathol; 1988 Dec; 90(6):641-52. PubMed ID: 2848408
[TBL] [Abstract][Full Text] [Related]
4. The value of immunohistochemical identification of neuroendocrine differentiation in non small cell lung carcinoma.
Słodkowska J
Rocz Akad Med Bialymst; 1997; 42 Suppl 1():23-7. PubMed ID: 9337520
[TBL] [Abstract][Full Text] [Related]
5. The value of neuroendocrine markers in non-small cell lung cancer: a comparative immunohistopathologic study.
Kiriakogiani-Psaropoulou P; Malamou-Mitsi V; Martinopoulou U; Legaki S; Tamvakis N; Vrettou E; Fountzilas G; Skarlos D; Kosmidis P; Pavlidis N
Lung Cancer; 1994 Dec; 11(5-6):353-64. PubMed ID: 7535640
[TBL] [Abstract][Full Text] [Related]
6. [Neuroendocrine markers in lung cancer].
Shen L
Zhonghua Bing Li Xue Za Zhi; 1993 Aug; 22(4):201-3. PubMed ID: 8168175
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine differentiation as an indicator of chemosensitivity and prognosis in nonsmall cell lung cancer.
Petrović M; Baskić D; Banković D; Ilić N
Biomarkers; 2011 Jun; 16(4):311-20. PubMed ID: 21595568
[TBL] [Abstract][Full Text] [Related]
8. The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer.
Graziano SL; Mazid R; Newman N; Tatum A; Oler A; Mortimer JA; Gullo JJ; DiFino SM; Scalzo AJ
J Clin Oncol; 1989 Oct; 7(10):1398-406. PubMed ID: 2550590
[TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer.
Carles J; Rosell R; Ariza A; Pellicer I; Sanchez JJ; Fernandez-Vasalo G; Abad A; Barnadas A
Lung Cancer; 1993 Dec; 10(3-4):209-19. PubMed ID: 7521264
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine differentiation in 32 cases of so-called sclerosing hemangioma of the lung: identified by immunohistochemical and ultrastructural study.
Xu HM; Li WH; Hou N; Zhang SG; Li HF; Wang SQ; Yu ZY; Li ZJ; Zeng MY; Zhu GM
Am J Surg Pathol; 1997 Sep; 21(9):1013-22. PubMed ID: 9298877
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of neuroendocrine phenotype in non-small-cell lung cancer.
Carnaghi C; Rimassa L; Garassino I; Santoro A
Ann Oncol; 2001; 12 Suppl 2():S119-23. PubMed ID: 11762337
[TBL] [Abstract][Full Text] [Related]
12. The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer.
Nisman B; Heching N; Biran H; Barak V; Peretz T
Tumour Biol; 2006; 27(1):8-16. PubMed ID: 16340245
[TBL] [Abstract][Full Text] [Related]
13. Nonsmall cell lung carcinoma with neuroendocrine differentiation--an entity of no clinical or prognostic significance.
Ionescu DN; Treaba D; Gilks CB; Leung S; Renouf D; Laskin J; Wood-Baker R; Gown AM
Am J Surg Pathol; 2007 Jan; 31(1):26-32. PubMed ID: 17197916
[TBL] [Abstract][Full Text] [Related]
14. Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer.
Lamy PJ; Grenier J; Kramar A; Pujol JL
Lung Cancer; 2000 Sep; 29(3):197-203. PubMed ID: 10996422
[TBL] [Abstract][Full Text] [Related]
15. Analysis of neuroendocrine markers, HER2 and CEA before and after chemotherapy in patients with stage IIIA non-small cell lung cancer: a Cancer and Leukemia Group B study.
Graziano SL; Kern JA; Herndon JE; Tatum A; Brisson ML; Memoli V; Sugarbaker D; Skarin AT; Kreisman H; Green MR
Lung Cancer; 1998 Sep; 21(3):203-11. PubMed ID: 9857998
[TBL] [Abstract][Full Text] [Related]
16. [Detection of neuroendocrine differentiation in NSCLC and its clinical significance].
Ouyang N; Chen G; Ding J
Zhonghua Jie He He Hu Xi Za Zhi; 2001 Feb; 24(2):90-2. PubMed ID: 11802946
[TBL] [Abstract][Full Text] [Related]
17. Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma.
Pelosi G; Pasini F; Sonzogni A; Maffini F; Maisonneuve P; Iannucci A; Terzi A; De Manzoni G; Bresaola E; Viale G
Cancer; 2003 May; 97(10):2487-97. PubMed ID: 12733148
[TBL] [Abstract][Full Text] [Related]
18. Reactivity of lung tumors with lung-derived and non-lung-derived monoclonal antibodies.
Ioachim HL; Pambuccian S; Giancotti F; Dorsett B
Int J Cancer Suppl; 1994; 8():132-3. PubMed ID: 7515026
[TBL] [Abstract][Full Text] [Related]
19. Neuroendocrine differentiation in non-small cell lung carcinomas.
Baldi A; Groger AM; Esposito V; Di Marino MP; Ferrara N; Baldi F
In Vivo; 2000; 14(1):109-14. PubMed ID: 10757067
[TBL] [Abstract][Full Text] [Related]
20. [Spindle cell carcinoma of breast with neuroendocrine differentiation].
Ding HY; Gao LX
Zhonghua Bing Li Xue Za Zhi; 2006 Jan; 35(1):13-7. PubMed ID: 16608642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
